The 2021 Edition of The Best Lawyers in Connecticut was recently released. View the digital edition now!

Best Lawyers logo
  • Lawyers
  • Methodology
  • NEW! Ones to Watch
  • Partnerships
  • Nominate a Lawyer
  • Log In
  • Lawyers
    • Advanced Search
    • COVID-19 Assistance
    • Featured Ones to Watch
    • Lawyer of the Year
    • Highlighted Lawyers
    • Nominate a Lawyer
  • Methodology
    • Overview
    • Ones to Watch
    • Editorial Timelines
    • Practice Areas
    • Publicizing Guidelines
    • FAQ
  • Publications
    • Connecticut
    • Injury & Malpractice
    • Pennsylvania
    • Georgia
    • Colorado
    • Family Law
    • New York Area
    • Canada
    • South Florida
    • Southern California
    • Northern California
    • Tampa
    • Midwest
  • Legal Insights
    • Featured Articles
    • In the News
    • Advisory Board
    • Meet the Board
    • Press & Events
  • About
    • Global Presence
    • Company History
    • Leadership
  • Ones to Watch
  • Partnerships
  • Nominate a Lawyer
  • Log In Log In
  • Nominate a Lawyer
  • Log In

Lawyer Profile

Image of James F. "Jim" Haley , Jr.

James F. "Jim" Haley , Jr.

Share:
Haley Guiliano LLP
  • Recognized Since:
    1991
  • Recognized in:
    Biotechnology and Life Sciences Practice
    Litigation - Intellectual Property...
  • Website:
    http://www.hglaw.com
  • Location:
    75 Broad Street, Suite 1000
    New York, NY 10004
  • LinkedIn

Jim has focused his practice on the worldwide procurement, defense and enforcement of patents in the biotechnology, biopharmaceutical, pharmaceutical and chemical industries. He has counseled biotechnology and biopharmaceutical clients since 1978 and drafted, prosecuted and defended some of the basic patents in recombinant DNA technologies. He has extensive experience in United States and worldwide patent prosecution and patent enforcement and defense in all areas of biotechnology and biopharmaceuticals.Prior to co-founding Haley Guiliano, Jim was a Senior Counsel and Partner of Ropes & Gray, where he was former co-head of the Intellectual Property Rights Management practice group, and a partner of Fish & Neave. At Fish & Neave, Jim established and led the firm’s Life Sciences Technical Advisor program and successfully mentored over seventy Ph.D.’s in the life sciences and organic chemistry as they transitioned from the laboratory, through law school, to attorneys at law, specializing in intellectual property procurement, counselling, defense and enforcement.

Jim has prosecuted and led the prosecution to issue of more than 700 United States patents and many thousands of related patents around the world. Among the technologies represented in these patents are new chemical entities, synthetic methods; methods of treatment, formulations, microorganisms and their uses, recombinant proteins and antibodies and their uses, viruses, vaccines, antigens, expression systems, DNA sequences and vectors, diagnostic kits, crystals, polymorphs, enzymes, prodrugs and methods of using them to treat disease, receptors and binding pockets, imaging modalities, transgenic plants and animals and their uses, polymers, and ion channels. See, in particular, U.S. Patent 4,563,423 (hepatitis B viral antigens and vaccines – recognized by IP Worldwide (2002) as among “10 Patents That Changed the World”), 4,530,901 (recombinant alpha interferon – first “hybridization” claim) and 5,756,466 (first pharmacophore claim).

Jim has led numerous United States and foreign patent litigations, European and other patent oppositions and United States interferences and other PTAB contested AIA proceedings in biotechnology and biopharmaceuticals.

Some of his representative patent infringement cases include: Trustees for Dartmouth College/ ChromaDex, Inc. v. Elysium Health (D. Del.), In the Matter of Certain L-Tryptophan, L-Tryptophan Products, And Their Methods of Production (U.S. International Trade Commission) (representing Petitioner C.J. Cheiljedang) (lead trial counsel) Regeneron Pharmaceuticals, Inc. v. Ablexis LLC (S.D.N.Y), Medac Pharma, Inc. et al v. Antares Pharma, Inc. et al (D.N.J.), Antares Pharma, Inc. v. Medac GmbH and Medac Pharma (D. Del), Genzyme v Anika Therapeutics (D. Mass.), Shelbyzyme v Genzyme (D. Del.), Genzyme v Seikagaku and Zimmer (D. Mass.), Genzyme v Medicis (D. Mass.), MEEI v. QLT/Novartis Ophthalmics (D. Mass), MEEI v. QLT (D. Mass) Amgen v. Aventis/TKT (D. Mass.), Oregon Health & Sciences University v. Vertex (D. Oregon), Pieczenik v. Dyax (D. Mass and S.D.N.Y.), Schering-Plough v. Sterling Winthrop (D. N.J.), Sheller Globe v. Milsco (D. Wisc.)), Square D v. 3M (N.D. Ill), PPG v. Celanese (E.D. P.A.), Chiron v. Vertex/Lilly (N.D. Cal.), Biogen/Harvard v. Pharmacia (D. Mass), Biogen v. Amgen (D. Mass), Biogen v. Berlex (D. Mass), Biogen v. Genentech/Roche (D. Mass), Schering v. Genentech (D. NJ), PPG v. Celanese (E.D. Pa), Case v. BASF (D. Mass) BASF v. United Carbide (S.D.N.Y.), Schering v. ISI/Busch Biotech (D. Del). Case v. BASF (D. Mass.), Amgen v. TKT/Aventis (UK), Biogen v. Boehringer Ingelheim (Germany, Austria, Poland), Boehringer Ingelheim v. Bioferon (Germany), Biogen v. Medeva (UK), Epix v. Bracco (France, Germany, Netherlands), Biogen v. Amgen (Japan), Biogen v. BTG (Israel), Biogen v. Scitech (Singapore), Biogen/Harvard University v. Sumitomo (Japan), Biogen/Harvard v. Pharmacia (Sweden).Jim's representative oppositions include: EPO (bonemorphogenetic protein), EPO (BAFF antibodies), EPO (IL-1 Inhibitor), EPO (phage display), EPO (expression vector), EPO (alpha interferon), EPO (hepatitis B viral antigens), EPO (gamma interferon), EPO (beta interferon), Germany (beta interferon), EPO (protein secretion), EPO (xenomice and antibodies), EPO (imaging agents), Australia (gamma interferon), Australia (antiviral compounds), Japan (beta interferon), Japan (protein secretion), Japan (alpha interferon), Japan (antiviral nucleosides).

Jim's representative interferences and contested proceedings before the PTAB (all as lead counsel) include: BAFF antibodies, BCR-ABL mutations in cancer diagnosis, Tweak proteins, IL-13 receptor, M-CSF antibodies, alpha interferon, hepatitis B viral antigens, protein secretion, leukocyte adhesion molecules, beta interferon, interleukin 1 converting enzyme inhibitors, and bone morphogenic proteins, CD40 counterreceptor antibodies, transgenic fibrinogen, single chain antibodies, methods of treating inflammatory disease with methotrexate, and feedback inhibition in tryptophan biosynthesis, YddG in tryptophan biosynthesis, HIV protease inhibitors, and swage mounts. See in particular, Fiers v. Revel, 984 F.2d 1164 (Fed. Cir. 1993); Velander v. Garner, 348 F. 3d 1359 (Fed. CIR. 2003); Noelle v. Lederman, 355 F.3d 1343 (Fed. Cir. 2004); Sanofi-Aventis v. Pfizer, Inc., 733 F.3d 1364 (Fed. Cir. 2013); and Koios Pharmaceuticals v. Medac GmbH, IPR2016-01370 (Final Decision, February 2018).

Continue Reading
  • Lawyer Bio
  • Client Comments
  • Lawyer Practice Areas
  • Firm Details

Lawyer Bio

Jim has focused his practice on the worldwide procurement, defense and enforcement of patents in the biotechnology, biopharmaceutical, pharmaceutical and chemical industries. He has counseled biotechnology and biopharmaceutical clients since 1978 and drafted, prosecuted and defended some of the basic patents in recombinant DNA technologies. He has extensive experience in United States and worldwide patent prosecution and patent enforcement and defense in all areas of biotechnology and biopharmaceuticals.Prior to co-founding Haley Guiliano, Jim was a Senior Counsel and Partner of Ropes & Gray, where he was former co-head of the Intellectual Property Rights Management practice group, and a partner of Fish & Neave. At Fish & Neave, Jim established and led the firm’s Life Sciences Technical Advisor program and successfully mentored over seventy Ph.D.’s in the life sciences and organic chemistry as they transitioned from the laboratory, through law school, to attorneys at law, specializing in intellectual property procurement, counselling, defense and enforcement.

Jim has prosecuted and led the prosecution to issue of more than 700 United States patents and many thousands of related patents around the world. Among the technologies represented in these patents are new chemical entities, synthetic methods; methods of treatment, formulations, microorganisms and their uses, recombinant proteins and antibodies and their uses, viruses, vaccines, antigens, expression systems, DNA sequences and vectors, diagnostic kits, crystals, polymorphs, enzymes, prodrugs and methods of using them to treat disease, receptors and binding pockets, imaging modalities, transgenic plants and animals and their uses, polymers, and ion channels. See, in particular, U.S. Patent 4,563,423 (hepatitis B viral antigens and vaccines – recognized by IP Worldwide (2002) as among “10 Patents That Changed the World”), 4,530,901 (recombinant alpha interferon – first “hybridization” claim) and 5,756,466 (first pharmacophore claim).

Jim has led numerous United States and foreign patent litigations, European and other patent oppositions and United States interferences and other PTAB contested AIA proceedings in biotechnology and biopharmaceuticals.

Some of his representative patent infringement cases include: Trustees for Dartmouth College/ ChromaDex, Inc. v. Elysium Health (D. Del.), In the Matter of Certain L-Tryptophan, L-Tryptophan Products, And Their Methods of Production (U.S. International Trade Commission) (representing Petitioner C.J. Cheiljedang) (lead trial counsel) Regeneron Pharmaceuticals, Inc. v. Ablexis LLC (S.D.N.Y), Medac Pharma, Inc. et al v. Antares Pharma, Inc. et al (D.N.J.), Antares Pharma, Inc. v. Medac GmbH and Medac Pharma (D. Del), Genzyme v Anika Therapeutics (D. Mass.), Shelbyzyme v Genzyme (D. Del.), Genzyme v Seikagaku and Zimmer (D. Mass.), Genzyme v Medicis (D. Mass.), MEEI v. QLT/Novartis Ophthalmics (D. Mass), MEEI v. QLT (D. Mass) Amgen v. Aventis/TKT (D. Mass.), Oregon Health & Sciences University v. Vertex (D. Oregon), Pieczenik v. Dyax (D. Mass and S.D.N.Y.), Schering-Plough v. Sterling Winthrop (D. N.J.), Sheller Globe v. Milsco (D. Wisc.)), Square D v. 3M (N.D. Ill), PPG v. Celanese (E.D. P.A.), Chiron v. Vertex/Lilly (N.D. Cal.), Biogen/Harvard v. Pharmacia (D. Mass), Biogen v. Amgen (D. Mass), Biogen v. Berlex (D. Mass), Biogen v. Genentech/Roche (D. Mass), Schering v. Genentech (D. NJ), PPG v. Celanese (E.D. Pa), Case v. BASF (D. Mass) BASF v. United Carbide (S.D.N.Y.), Schering v. ISI/Busch Biotech (D. Del). Case v. BASF (D. Mass.), Amgen v. TKT/Aventis (UK), Biogen v. Boehringer Ingelheim (Germany, Austria, Poland), Boehringer Ingelheim v. Bioferon (Germany), Biogen v. Medeva (UK), Epix v. Bracco (France, Germany, Netherlands), Biogen v. Amgen (Japan), Biogen v. BTG (Israel), Biogen v. Scitech (Singapore), Biogen/Harvard University v. Sumitomo (Japan), Biogen/Harvard v. Pharmacia (Sweden).Jim's representative oppositions include: EPO (bonemorphogenetic protein), EPO (BAFF antibodies), EPO (IL-1 Inhibitor), EPO (phage display), EPO (expression vector), EPO (alpha interferon), EPO (hepatitis B viral antigens), EPO (gamma interferon), EPO (beta interferon), Germany (beta interferon), EPO (protein secretion), EPO (xenomice and antibodies), EPO (imaging agents), Australia (gamma interferon), Australia (antiviral compounds), Japan (beta interferon), Japan (protein secretion), Japan (alpha interferon), Japan (antiviral nucleosides).

Jim's representative interferences and contested proceedings before the PTAB (all as lead counsel) include: BAFF antibodies, BCR-ABL mutations in cancer diagnosis, Tweak proteins, IL-13 receptor, M-CSF antibodies, alpha interferon, hepatitis B viral antigens, protein secretion, leukocyte adhesion molecules, beta interferon, interleukin 1 converting enzyme inhibitors, and bone morphogenic proteins, CD40 counterreceptor antibodies, transgenic fibrinogen, single chain antibodies, methods of treating inflammatory disease with methotrexate, and feedback inhibition in tryptophan biosynthesis, YddG in tryptophan biosynthesis, HIV protease inhibitors, and swage mounts. See in particular, Fiers v. Revel, 984 F.2d 1164 (Fed. Cir. 1993); Velander v. Garner, 348 F. 3d 1359 (Fed. CIR. 2003); Noelle v. Lederman, 355 F.3d 1343 (Fed. Cir. 2004); Sanofi-Aventis v. Pfizer, Inc., 733 F.3d 1364 (Fed. Cir. 2013); and Koios Pharmaceuticals v. Medac GmbH, IPR2016-01370 (Final Decision, February 2018).

Read more on firm website
  • Award List
  • Additional Information

Recognized in The Best Lawyers in America for work in:

  • Biotechnology and Life Sciences Practice
  • Litigation - Intellectual Property
  • Litigation - Patent

Special Focus:

  • Patent
 

Lawyer Client Comments

Lawyer Practice Areas

Key: Awarded in Best Lawyers Not Currently Awarded for this Area in Best Lawyers

Firm Details

Image for Haley Guiliano LLP View Firm Profile
Haley Guiliano LLP
http://www.hglaw.com
 
3 Office Locations
in 2 Countries

United Kingdom

United Kingdom

London, United Kingdom

26-28 Bedford Row, 2nd Floor

London WC1R 4HE

United Kingdom

44 20 8158 3000

Get Directions

United States

United States

California

California

San Jose, CA

111 North Market Street, Suite 900

San Jose, CA 95113

United States

(669) 213.1050

Get Directions

New York

New York

New York, NY

75 Broad Street, Suite 1000

New York, NY 10004

United States

(646) 973.2500

Get Directions

 
Add Comment
In making your comments, please do not refer to a pending legal matter.
(*) Required Fields
There was an error during saving, please try again.
If you continue to get this message, please contact us at info@bestlawyers.com or 803.648.0300 for assistance.
Please complete the captcha then submit.
Your comment was saved successfully!
Thank you for your feedback.
  • Find a Lawyer
  • Nominate a Lawyer
  • Legal Insights
  • Contact Us
Lawyers 
  • Advanced Search
  • COVID-19 Assistance
  • Featured Ones to Watch
  • Lawyer of the Year
  • Highlighted Lawyers
  • Nominate a Lawyer
  • Find a Lawyer
Methodology
  • Overview
  • Ones to Watch
  • Editorial Timelines
  • Practice Areas
  • Publicizing Guidelines
  • FAQ
Publications
  • Business Editions
  • Regional Editions
  • Partnerships
  • Become a Contributor
Legal Insights
  • Featured Articles
  • In the News
  • Advisory Board
  • Meet the Board
  • Press & Events
  • Best Law Firms
  • Subscribe
About
  • Global Presence
  • Company History
  • Leadership
  • Founders
  • Press Releases
  • Testimonials
  • Contact Us
  • Careers
My Account
  • Log In
  • Store
  • Marketing Guidance
Best Lawyers Best Lawyers logo +1-803-648-0300
801 Broad Street, Suite 950 Augusta, GA 30901
  • Twitter
  • LinkedIn
  • Facebook
  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Lawyer Directory
  • Best Law Firms

© 2010-2021 Best Lawyers — All Rights Reserved.

BL Icon

LEGAL INSIGHTS

by Best Lawyers®



Get the latest insights on the news, trends, and people that shape the global legal field with our weekly email digest.




Subscribe



PRIVACY POLICY

Thank you for subscribing.